A new article published in Diabetes Therapy aimed to identify patient characteristics and on treatment effects that may have contributed to the different outcomes in younger 65 years patients versus in older patients 8805 65 years with type 2 diabetes mellitus T2DM in a previous meta analysis the results of which had indicated a 37 relative risk reduction in prospectively adjudicated major adverse cardiac events MACEs comprising of non fatal myocardial infarction non fatal stroke cardiovascular CV death with vildagliptin versus comparators. This study entailed an analysis of on treatment differences vildagliptin versus comparators for the change from baseline in CV risk factors. It was observed that patients aged 65 years had shorter diabetes duration and slightly higher glycated hemoglobin HbA1c at baseline than patients aged 8805 65 years. Whereas more patients in the 8805 65 year age group had hypertension dyslipidemia and a history of CV events. On the other hand there were statistically significant differences in the change in HbA1c and total cholesterol in favor of vildagliptin relative to comparators which were consistent in both age groups. While marked differences were observed in the reduction in systolic blood pressure SBP low density lipoprotein LDL cholesterol and weight in patients 65 years. Furthermore the incidence of hypoglycemic events was lower in patients treated with vildagliptin than with comparators. From the results it was concluded that vildagliptin had positive effects on SBP LDL cholesterol hypoglycemia and body weight in younger patients with T2DM.